Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

FDA Confirms Decision to Withdraw Melphalan Flufenamide Approval in Multiple Myeloma

February 23rd 2024

The FDA has determined that sufficient criteria have been met to withdraw the approval for melphalan flufenamide in patients with multiple myeloma.

Cilta-Cel Sustains MRD-Negative Responses in Previously Treated Multiple Myeloma

February 23rd 2024

Cilta-cel continues to elicit deep and durable responses in patients with early relapsed multiple myeloma, including those refractory to lenalidomide.

CHMP Recommends Approval of Cilta-Cel for Early Relapsed/Refractory Multiple Myeloma

February 23rd 2024

The Committee for Medicinal Products for Human Use has recommended the approval of cilta-cel for earlier-line relapsed/refractory multiple myeloma.

FDA Grants Priority Review to Linvoseltamab for Relapsed/Refractory Multiple Myeloma

February 21st 2024

A biologics license application for linvoseltamab in relapsed/refractory multiple myeloma has been accepted for priority review by the FDA.

FDA Approves Bi-weekly Teclistamab Dosing for Relapsed/Refractory Multiple Myeloma

February 20th 2024

The FDA has approved a supplemental Biologics License Application for teclistamab-cqyv (Tecvayli) at a reduced dose of 1.5 mg/kg every 2 weeks in patients with relapsed/refractory multiple myeloma who have achieved and maintained a complete response or greater for at least 6 months.

Dr Zonder on the Outcomes of the PERSEUS Trial in Multiple Myeloma

February 20th 2024

Jeffrey Zonder, MD, discusses the outcomes of the phase 3 PERSEUS trial in patients with relapsed/refractory multiple myeloma.

Treatment Considerations and Sequencing in Multiple Myeloma

February 19th 2024

The expert panel concludes their discussion with clinical insights on treatment sequencing and therapeutic decision-making for patients who have relapsed.

CAR T-Cell Therapy in Multiple Myeloma: Role in the Treatment Landscape

February 19th 2024

A roundtable discussion on the evolving treatment landscape surrounding CAR T-cell therapy in multiple myeloma, with a focus on future directions and the management of adverse events.

Dr Baz on the Incidence of AEs With Ide-Cel in Triple-Class–Exposed Multiple Myeloma

February 16th 2024

Rachid Baz, MD, discusses findings from an analysis of cytopenias and infections in patients with multiple myeloma enrolled in the KarMMa-3 trial.

Dr Mikhael on Research Developments in Multiple Myeloma

February 15th 2024

Joseph Mikhael, MD, discusses treatment advancements and ongoing research in multiple myeloma.

Dr Parrondo on the RedirecTT-1 Trial of Teclistamab Plus Talquetamab in Multiple Myeloma

February 14th 2024

Ricardo D. Parrondo, MD, discusses the phase 1b/2 RedirecTT-1 of teclistamab and talquetamab in relapsed/refractory multiple myeloma.

Dr Zonder on Unmet Needs to be Addressed in Multiple Myeloma

February 13th 2024

Jeffrey Zonder, MD, discusses notable unmet needs that remain to be addressed in the treatment of patients with relapsed/refractory multiple myeloma.

GPRC5D-Targeting Bispecifics in Multiple Myeloma

February 12th 2024

The expert panel discusses recent clinical trial data on GPRC5D-targeting bispecific antibodies and how they apply to the multiple myeloma treatment paradigms.

Adverse Effects Related to Bispecifics in Multiple Myeloma

February 12th 2024

Comprehensive insights on the adverse effects seen from bispecific antibodies in the treatment of patients with multiple myeloma.

Data From 2023 ASH Annual Meeting Provide Positive Updates in Multiple Myeloma

February 11th 2024

Experts discuss treatment in newly diagnosed multiple myeloma and the role of CAR T-cell therapies and bispecifics in relapsed/refractory disease.

Dr Dima on the Mechanism of Action of Teclistamab in Relapsed/Refractory Multiple Myeloma

February 9th 2024

Danai Dima, MD, discusses the mechanism of action of teclistamab and why real-world outcomes with the agent were evaluated in a retrospective study.

Dr Siegel on the Rationale for Investigating KID in Multiple Myeloma

February 8th 2024

David Samuel Dicapua Siegel, MD, discusses a trial of carfilzomib, iberdomide, and dexamethasone in newly diagnosed, transplant-eligible multiple myeloma.

Retrospective Review Sheds Light on Real-World Efficacy With Teclistamab in R/R Myeloma After BCMA-Directed Therapy

February 8th 2024

Teclistamab produced responses in real-world patients with relapsed and refractory multiple myeloma and prior exposure to BCMA-targeted therapy.

Dr Parrondo on the Investigation of GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma

February 7th 2024

Ricardo D. Parrondo, MD, discusses the exploration of the non-BCMA CAR T-cell target GPRC5D in multiple myeloma.

Belantamab Mafodotin Plus Vd More Than Doubles PFS in Relapsed/Refractory Multiple Myeloma

February 6th 2024

Belantamab mafodotin plus bortezomib and dexamethasone improved PFS vs daratumumab plus bortezomib and dexamethasone in relapsed/refractory myeloma.